Welcome to our dedicated page for Atreca news (Ticker: BCEL), a resource for investors and traders seeking the latest updates and insights on Atreca stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atreca's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atreca's position in the market.
Atreca, a biotechnology company listed under NASDAQ: BCEL, will participate in several upcoming virtual investor conferences in November and December 2020. The events include the Cowen 2020 Next IO Summit on November 13, Stifel 2020 Virtual Healthcare Conference on November 18, and Evercore ISI 3rd Annual HealthCONx on December 2, where Atreca will discuss cancer target identification. Live audio webcasts of the presentations can be found on their website, with replays available for 90 days post-event.
Atreca, Inc. (NASDAQ: BCEL) announced two upcoming poster presentations on ATRC-101, a novel immunotherapy targeting tumor-associated ribonucleoprotein complexes, at the SITC 2020 conference, scheduled for November 9-14, 2020. The first poster will discuss the synergy of ATRC-101 with PD-1/PD-L1 inhibitors, while the second will showcase its single-agent efficacy in mouse tumor models. Currently in Phase 1b clinical trials, ATRC-101 has displayed significant anti-tumor activity against various cancers. For more details, abstracts will be accessible on the SITC and Atreca websites.
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), will present at two upcoming investor conferences. The 2020 Wedbush PacGrow Healthcare Virtual Conference is scheduled for August 12, 2020, at 2:20 p.m. EDT, while the Canaccord Genuity 40th Annual Growth Conference will take place on August 13, 2020, at 4:00 p.m. EDT. Interested investors can access live webcasts through the company's website, with archived replays available for 90 days post-event. Atreca is known for its antibody-based immunotherapeutics and is currently enrolling patients for its Phase 1b study on ATRC-101.
Atreca (Nasdaq: BCEL) announced the pricing of an underwritten public offering of 7,031,250 shares of Class A Common Stock and 781,250 shares of Class B Common Stock at $16.00 per share, aiming for gross proceeds of $125 million. A 30-day option for underwriters to purchase up to 1,171,875 additional Class A shares is included. The offering is expected to close by July 20, 2020, pending customary conditions. The offering's details were registered with the SEC, with a prospectus available through designated contacts.
Atreca, Inc. (Nasdaq: BCEL) announced a proposed underwritten public offering of its Class A Common Stock. The company plans to grant underwriters a 30-day option to purchase additional shares. Cowen and Company, Evercore Group, and Stifel Nicolaus are acting as joint book-running managers. The offering is subject to market conditions, and there are no assurances on completion or terms. A shelf registration statement was filed with the SEC and a prospectus will be available. Forward-looking statements regarding the offering's completion involve risks and uncertainties.
Atreca and Xencor have announced a three-year collaboration to develop T cell-engaging bispecific antibodies aimed at treating cancer. The partnership will utilize Xencor’s XmAb technology and Atreca's antibody-target pairs from their unique discovery platform. Both companies will share costs and profits equally, with each leading development on one of the selected joint programs. Additionally, they can independently pursue up to two programs, with royalties on net sales. The collaboration builds on prior efforts initiated in 2019.
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), will present preclinical data on its lead candidate ATRC-101 in a webinar on June 15, 2020. The presentation will include insights on the novel target and mechanism of action for ATRC-101, along with clinical study plans. ATRC-101, a monoclonal antibody, is designed to engage the innate immune system and has shown promising anti-tumor activity in preclinical studies across various cancer types. The findings support ongoing development aimed at human testing.
Atreca, a clinical-stage biotechnology company focused on novel therapeutics, reported its financial results for Q1 2020. As of March 31, 2020, the company had $166.3 million in cash, cash equivalents, and investments. It incurred R&D expenses of $14.2 million and G&A expenses of $7.1 million, resulting in a net loss of $20.4 million, or $0.73 per share. Despite challenges posed by the COVID-19 pandemic, Atreca continues patient enrollment in its Phase 1b trial for ATRC-101 and has formed collaborations to develop COVID-19 treatments.
Atreca (NASDAQ: BCEL) announced its participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference, scheduled for May 19 at 11:30 a.m. EDT. The company specializes in developing novel therapeutics through its unique discovery platform that leverages the human immune response. Investors can access a live audio webcast of the presentation on Atreca's website, with a replay available for 90 days post-event. Atreca is advancing its lead product candidate, ATRC-101, currently in a Phase 1b study targeting multiple solid tumor cancers.